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Case report
A 59-year-old Caucasian male had a 28-year history
of episodes of recurrent urticaria, fever, periorbital
angio-oedema and conjunctival injection. The epi-
sodes would be preceded by prodromal symptoms
of nightmares, general malaise/fatigue and anterior
chest/upper abdominal pain similar to indigestion.
This would then proceed to urticaria, which had
been described as atypical, not always being raised
or palpable but being intensely itchy (Figure 1), as
well as fever, periorbital angio-oedema and some-
times gum or jaw pain. Four to 6 h after onset, symp-
toms would typically proceed to hypotension
resulting in the loss of consciousness on several oc-
casions. Attacks would last 3–4 days, and were fol-
lowed by fatigue lasting 1–2 weeks.
Investigations showed a monoclonal immuno-
globulin G (IgG) kappa paraprotein that has fluctu-
ated between 14 and 20 g/l throughout the course of
his illness, although without increasing trend. Hewas
also found to have low levels of kappa free light
chains on urine electrophoresis. He had low C4 com-
plement levels and C3 complement levels at the
lower end of the normal range during remission,
with raised C3d and elevated amounts of the terminal
component complex, consistent with ongoing com-
plement activation. Other investigations taken during
remission, including C1 inhibitor levels; full blood
count; renal and liver function; thyroid function;
erythrocyte sedimentation rate (ESR); and C-reactive
protein (CRP), did not show any significant abnor-
mality. Anti-nuclear and anti-neutrophil cytoplasmic
antibodies were not detected.
Subsequently, he was admitted for observation
during an attack. Investigations done at that time
showed a markedly increased CRP of >250mg/l,
leucopenia and thrombocytopenia (with a nadir
white cell count of 0.7 109/l, neutrophil count of
0.1109/l and platelet count of 28 109/l) and
decreased complement C3 and C4 levels. The ESR
did not show a concomitant rise with the CRP and
was within normal limits. No cryoproteins were
isolated. Serial mast cell tryptase levels were not
elevated during the attack. This laboratory result pic-
ture could have been consistent with active systemic
lupus erythematosus or severe sepsis. However,
anti-nuclear antibody was negative, urea and elec-
trolytes remained normal, and there was no other
clinical evidence of lupus. Multiple blood cultures
and viral polymerase chain reaction investigations
did not reveal a microbe.
It should be noted that the marked laboratory
abnormalities were delayed by a day after onset of
severe symptoms, during this and subsequent epi-
sodes where corticosteroid treatment was delayed.
All laboratory abnormalities returned to baseline
following the attack. Figure 2 shows the progression
of these investigations during one of his acute
attacks. Despite the severe neutropenia, treatment
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with granulocyte colony-stimulating factor and
broad spectrum antibiotics was unnecessary as the
fever and cytopenias spontaneously resolved.
A bone marrow biopsy was normocellular with
plasma cells <5%. A skin biopsy of one of the
lesions showed mild dermal oedema, consistent
with urticaria, but without any specific pathologic
features. Radiological imaging did not show evi-
dence of hepatomegaly, splenomegaly and lymph-
adenopathy on computed tomography scanning.
A skeletal survey showed no abnormalities.
To determine if his symptoms were due to a peri-
odic fever syndrome, genetic testing of FEMV,
TNFRSF1A, NLRP3 and MVK (for FMF, TRAPS,
CAPS and HIDS, respectively) was undertaken, but
no mutations were detected within the exons that
have previously been associated with disease caus-
ing mutations in these genes.
A diagnosis of monoclonal gammopathy of uncer-
tain significance, rather than myeloma, was made
and no further specific treatment for this was indi-
cated. Various therapeutic options to treat and
reduce the frequency of his attacks were tried.
Antihistamines and tranexamic acid may have
helped reduced the urticaria but did not prevent
progression of the associated symptoms. Neither
C1 inhibitor nor anakinra significantly modified
the course of the attacks. Oral prednisolone
(30–40mg daily for 3 days) was found to be helpful
in aborting or reducing the severity of attacks
when commenced in the prodromal stage. He was
subsequently commenced on subcutaneous im-
munoglobulin replacement therapy because of the
evidence of development of immune paresis and the
identification of respiratory tract infection as a trig-
ger for attacks.
Discussion
The auto-inflammatory syndromes represent a group
of disorders characterized by recurrent fever asso-
ciated with systemic inflammatory symptoms affect-
ing joints, skin, muscles and eyes (reviewed in
Goldbach-Mansky1). They are thought to be due to
dysregulation of the innate immune system, result-
ing in episodes of spontaneous inflammation.
Typically, there is absence of autoimmune reactivity
with no detectable auto-antibodies or auto-reactive
T cells.
Initially, the auto-inflammatory syndromes were
taken to encompass the hereditary recurrent fever
syndromes, but with time the umbrella term has
expanded to include a broader range of diseases.
The recognized monogenic disorders resulting
in an auto-inflammatory syndrome include the
hereditary periodic fever syndromes: familial
Mediterranean fever (FMF), TNF receptor-associated
periodic syndrome (TRAPS), mevalonate kinase defi-
ciency (previously known as hyper-immunoglobulin
D syndrome, HIDS), the cryopyrin-associated peri-
odic syndromes (CAPS), Blau syndrome, deficiency
of interleukin-1-receptor antagonist and pyogenic
arthritis, pyoderma gangrenosum and acne syn-
drome (PAPA). Other auto-inflammatory diseases
of uncertain genetic aetiology include periodic
fever, aphtous stomatitis, pharyngitis and adenitis
syndrome; Majeed syndrome, associated with
chronic recurrent multifocal osteomyelitis, congeni-
tal dyserythropoietic anaemia and neutrophilic
dermatosis; and Behcet’s disease. Acquired auto-
inflammatory syndromes such as Schnitzler’s
syndrome can also occur. Almost all of the auto-
inflammatory disorders respond to treatment with
interleukin (IL)-1 antagonism, and a number of con-
ditions (including HIDS, Majeed syndrome, TRAPS,
PAPA and Blau syndrome) respond to corticosteroid
therapy.1
Schnitzler’s syndrome is the occurrence of urti-
caria and a monoclonal paraprotein (typically
IgM). Other associated features include the presence
of fever, raised inflammatory markers, hepatomeg-
aly, splenomegaly, lymphadenopathy, bony pain,
arthritis/arthralgia and bone abnormalities.2–4
It was originally described in 1972 and is relatively
rare4 with a total of approximately 100 patients
described in the literature, mostly in case reports.2
Lipsker et al.3 proposed a set of diagnostic criteria
that included the presence of two major criteria—
chronic urticarial rash and a monoclonal IgM para-
protein along with two of any of the following minor
criteria: recurrent fever, arthralgia or arthritis, bone
pain, lymphadenopathy, hepato- or splenomegaly
and an acute phase response (leucocytosis or
Figure 1. Photograph of rash during attacks.
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Figure 2. Graph showing serial white cell count, platelets, CRP, complement C3 and complement C4 during, before and
after an acute inflammatory attack. The dashed lines represent the reference ranges for the individual parameters.
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elevated ESR/CRP). Other causes that can result in a
similar symptom complex also need to be excluded.
More recently, a Schnitzler syndrome variant has
been described with a monoclonal IgG paraprotein
(instead of IgM).5–7
Our patient fulfils criteria for a diagnosis of IgG
variant Schnitzler’s syndrome. However, there are
some atypical features to indicate that our patient’s
syndrome is pathologically distinct, and represents
another form of auto-inflammatory disease asso-
ciated with a monoclonal gammopathy.
Of note, Schnitzler’s syndrome is associated with
lymphadenopathy (44% of the patients) and hepa-
tosplenomegaly (12% of the patients), as well as a
leucocytosis (69% of patients) during attacks.2 Our
patient had none of those features and conversely
had marked neutropenia (as part of pancytopenia),
most likely due to immune complex-mediated con-
sumption. In addition, there was marked activation
of the complement cascade, with decreased levels
of early classical complement components and
increased terminal components. Complement acti-
vation has been proposed as a possible pathophy-
siological mechanism for Schnitzler’s syndrome;
however, complement components have been
either normal or elevated in reported cases,2
with reduced levels indicating either an alternative
diagnosis (e.g. cryoglobulinaemia)8 or genetic defi-
ciency,9 neither of which our patient had.
Another unusual feature is that in terms of treat-
ment response, our patient had an absent response
to anakinra unlike other patients with Schnitzler’s
syndrome treated with this biological agent.2,10
Instead, our patient has responded to treatment
with oral steroids. In classical Schnitzler’s syndrome,
the response to steroids is more variable with only
39% of the patients obtaining complete resolution
of symptoms.2 The IL-1/IL–1RA pathway is thought
to play a major role in the development of
Schnitzler’s syndrome (as well as many of the
other auto-inflammatory syndromes). However, it
is likely in our patient that either the IL1 pathway
is not playing a significant role or that other mech-
anisms are more important. A strong possibility in
this case is that complement activation due to
immune complex deposition might be initiating the
inflammatory cascade.
Many inflammatory stimuli (e.g. various bacterial
products including lipopolysaccharide) can concur-
rently trigger IL-1 secretion and complement acti-
vation (in addition to many other inflammatory
mediators). However, there is limited data investi-
gating the role of complement alone in the activa-
tion of IL-1, and this has shown conflicting results.
Plasma purified C5a and C3a have been shown to
stimulate IL-1 production from mouse macrophages
and human peripheral blood mononuclear cells
(PBMC).11–13 Conversely, there have been some
studies showing no secretion of IL-1 from rabbit
mononuclear cells or human PBMCs after stimula-
tion with purified and recombinant complement
fractions.14,15 A further study using recombinant
C5a showed induction of transcription (but not
translation) of IL-1 from PBMCs, in contrast to lipo-
polysacccharide, which resulted in transcription and
translation of IL-1.16 There is data showing that com-
plement, and the membrane attack complex in par-
ticular, promotes release of IL-1a from endothelial
cells.17 Hence, it is unclear whether complement
activation alone (in absence of other signals) results
in IL-1 release. Although not definitive, the labora-
tory data suggest that in some circumstances, com-
plement activation does not necessarily result in IL-1
production; consistent with the findings in our pa-
tient of complement activation and inflammation
but no response to IL-1 antagonism.
Conclusion
We present a case of monoclonal gammopathy-
related auto-inflammatory syndrome distinguished
from Schnitzler’s syndrome by complement activa-
tion, neutropenia and an absent response to ana-
kinra. We believe that this patient manifests a
new auto-inflammatory syndrome not previously
described. Features of the syndrome include:
 monoclonal paraprotein;
 ongoing classical pathway complement consumption;
 intermittent fever, rash and hypotension;
 transient leucopenia and thrombocytopenia, and
severe complement depletion following initial
symptoms;
 resistance to IL1 antagonists; and
 acute attacks terminated by corticosteroids.
Despite some similarities to Schnitzler’s syn-
drome, the symptoms primarily relate to comple-
ment activation rather than IL1 production. In such
cases, treatment modalities other than anakinra may
need to be considered to dampen down the
inflammation.
We propose naming this Mullins’ syndrome after
the patient described.
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